Highlights

  • Cynata Therapeutics shares rose 7.27% to AUD 0.30 during the afternoon session on 3 June 2026.
  • The company received a Positive Opinion from the European Medicines Agency's Paediatric Committee (PDCO) for the Paediatric Investigation Plan (PIP) relating to CYP-001.
  • Positive Phase 2 adult trial results are expected in late June or early July 2026.
  • CYP-001 previously reported an 87% Overall Response Rate and 60% two-year overall survival in a Phase 1 study of steroid-resistant aGvHD.
  • Europe represents a significant potential market opportunity, with more than 20,000 allogeneic stem cell transplants performed annually.

Cynata Therapeutics Ltd (ASX:CYP) shares advanced 7.27% to AUD 0.30 during the afternoon session on 3 June 2026 after the clinical-stage biotechnology company announced a favourable regulatory development for its lead cell therapy candidate, CYP-001. The gain adds to an already notable longer-term performance, with the stock remaining up 73.53% over the past year.

Investor attention appeared focused on the company's announcement that the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) had issued a Positive Opinion on the Paediatric Investigation Plan (PIP) for CYP-001 in acute graft-versus-host disease (aGvHD). The development represents an important regulatory step as Cynata continues advancing its commercialisation and late-stage clinical development strategy in Europe.

About Cynata Therapeutics

Cynata Therapeutics is an Australian clinical-stage biotechnology company specialising in stem cell and regenerative medicine therapies. The company develops treatments using its proprietary Cymerus™ platform, which utilises induced pluripotent stem cells (iPSCs) to produce mesenchymal stem cells (MSCs) at commercial scale.

The technology is designed to address several challenges associated with conventional MSC Manufacturing, including donor dependence, product variability and scalability constraints. Through this platform, Cynata is progressing a range of therapeutic programs targeting conditions where immune modulation and tissue repair may provide clinical benefits.

Its development portfolio includes programs in graft-versus-host disease, kidney transplantation, diabetic foot ulcers and osteoarthritis, while preclinical research has explored applications across a number of additional disease areas.

European Regulatory Milestone for CYP-001

The latest announcement centres on CYP-001, Cynata's Cymerus™-derived MSC product developed for intravenous administration.

The EMA's Paediatric Committee has endorsed the company's proposed Paediatric Investigation Plan, a regulatory requirement that must be agreed before a Phase 3 clinical trial can commence within the European Union. Importantly, this requirement applies regardless of whether a future Phase 3 study enrols adults, children or both.

Under the approved framework, Cynata intends to conduct a single randomised controlled Phase 2/3 trial involving approximately 72 paediatric patients suffering from acute graft-versus-host disease. Participants in the study are expected to range in age from 28 days to 18 years.

The company currently plans to prioritise a Phase 3 trial in adults before commencing the paediatric study. According to the agreed pathway, the paediatric trial would begin after completion of the primary analysis from the adult Phase 3 study.

The Positive Opinion will now proceed to the European Commission for formal adoption, representing another step toward advancing the therapy through the European regulatory process.

Addressing a Serious Unmet Medical Need

Acute graft-versus-host disease remains one of the most serious complications associated with bone marrow transplantation and related procedures.

The condition occurs when donor immune cells attack the recipient's tissues following transplantation. According to information provided by Cynata, aGvHD affects up to half of patients receiving transplants from another donor.

Current treatment Options are limited, particularly for patients who Fail to respond to steroid therapy. Approximately 50% of patients treated with first-line steroid therapy develop steroid-resistant acute graft-versus-host disease (SR-aGvHD), a condition associated with historically poor outcomes.

The company noted that historical two-year survival rates for patients with steroid-resistant disease have been reported at below 20%, highlighting the need for improved therapeutic approaches.

Given the severity of the condition and the limited number of available treatment options, regulatory progress for therapies targeting this indication often attracts investor attention.

Clinical Results Have Supported Continued Development

CYP-001 has previously delivered encouraging results in clinical studies, which have contributed to the company's continued Investment in the program.

In a Phase 1 trial involving adults with steroid-resistant acute graft-versus-host disease, the therapy achieved an Overall Response Rate of 87%. Complete Response Rate reached 53%, while overall survival at two years was reported at 60%.

The company also stated that no serious adverse events or safety concerns related to CYP-001 treatment were observed during the study.

Those findings subsequently led to two publications in the scientific Journal Nature Medicine, helping establish a clinical foundation for subsequent development activities.

While investors are closely monitoring future trial outcomes, the earlier data has provided the rationale for advancing the therapy into larger and later-stage studies.

Attention Turns to Upcoming Phase 2 Data

Another notable aspect of the update is the approaching release of Phase 2 trial results.

Cynata reported that the primary evaluation period for its Phase 2 study in adults with high-risk acute graft-versus-host disease was completed in March 2026.

The study enrolled a total of 65 participants across Australia, the United States and Europe. Patients were randomised to receive either steroids combined with CYP-001 or steroids combined with placebo.

The primary endpoint of the study is Overall Response Rate at Day 28.

Management indicated that results from this trial are anticipated in late June or early July 2026, making the upcoming data release a significant event for the company's lead development program.

Subject to favourable outcomes from the Phase 2 study, Cynata's current development strategy contemplates a Phase 3 trial in adults followed by the separate paediatric Phase 2/3 trial now endorsed by the PDCO.

In both future studies, patients are expected to be randomised between treatment with steroids plus CYP-001 and steroids plus placebo.

European Market Opportunity Remains Significant

Beyond the immediate regulatory implications, the update also highlighted the importance of the European market for Cynata's long-term plans.

According to the company, acute graft-versus-host disease is more prevalent in Europe than in any other region globally.

More than 20,000 allogeneic haematopoietic stem cell transplants are performed annually across Europe, compared with fewer than 10,000 in the United States.

This higher transplant activity contributes to a larger patient population potentially affected by acute graft-versus-host disease.

The company further noted that there are currently no EMA-approved cell-based therapies available for treating aGvHD in either adult or paediatric patients.

Management believes the regulatory progress achieved through the PIP process could support future commercialisation efforts should clinical development continue successfully.

Development Plan Supports Future Regulatory Flexibility

An additional benefit arising from the agreed PIP relates to the timing of future regulatory submissions.

Under the pathway accepted by the PDCO, Cynata may be able to submit a Marketing Authorisation Application for adult use while the paediatric clinical trial remains underway.

This could provide a more flexible regulatory timeline, allowing progress toward adult commercialisation without waiting for completion of the paediatric study.

The alignment between the company's proposed development strategy and the EMA committee's recommendations removes an important regulatory uncertainty as planning for later-stage studies continues.

What This Means for Investors

Cynata's latest announcement represents a favourable regulatory development for its lead therapeutic candidate and provides greater clarity around the pathway toward late-stage clinical development in Europe.

The Positive Opinion from the EMA's Paediatric Committee supports the company's planned clinical strategy for CYP-001 and reinforces progress toward potential future commercialisation opportunities within an important market.

Investor focus is also likely to remain on the upcoming Phase 2 trial results expected in late June or early July 2026. Those results are anticipated to play a significant role in determining the next phase of development for CYP-001 and could influence future regulatory and clinical milestones.

With shares gaining 7.27% on the day and remaining up 73.53% over the past year, the market appears to be closely following developments surrounding Cynata's lead cell therapy program and its advancement through key regulatory and clinical stages.